DENTSPLY SIRONA Inc. $XRAY Shares Acquired by AXQ Capital LP

AXQ Capital LP increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 105.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 172,815 shares of the medical instruments supplier’s stock after acquiring an additional 88,555 shares during the period. AXQ Capital LP’s holdings in DENTSPLY SIRONA were worth $1,975,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in DENTSPLY SIRONA in the first quarter valued at $26,000. Goldman Sachs Group Inc. raised its stake in DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares in the last quarter. Empowered Funds LLC raised its stake in DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after buying an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in DENTSPLY SIRONA by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after buying an additional 41,579 shares in the last quarter. Finally, Focus Partners Wealth raised its stake in DENTSPLY SIRONA by 59.1% in the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after buying an additional 9,355 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on XRAY. Barrington Research lifted their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, March 2nd. UBS Group cut their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Wells Fargo & Company lifted their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Finally, Citigroup began coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They set a “sell” rating and a $10.00 target price on the stock. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $13.82.

DENTSPLY SIRONA Price Performance

Shares of XRAY opened at $10.02 on Tuesday. DENTSPLY SIRONA Inc. has a twelve month low of $9.40 and a twelve month high of $17.09. The stock’s 50 day moving average is $11.24 and its two-hundred day moving average is $11.74. The firm has a market capitalization of $2.01 billion, a PE ratio of -3.18, a P/E/G ratio of 1.24 and a beta of 0.89. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The business had revenue of $880.00 million during the quarter, compared to analysts’ expectations of $841.80 million. During the same period in the prior year, the firm posted $0.43 EPS. DENTSPLY SIRONA’s revenue for the quarter was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Gregory T. Lucier purchased 15,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were acquired at an average price of $12.45 per share, with a total value of $186,750.00. Following the purchase, the director directly owned 65,000 shares of the company’s stock, valued at $809,250. The trade was a 30.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James D. Forbes purchased 5,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were purchased at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $124,800. This represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.